Who Paid My Doc
Peter Phan
Nuclear Medicine Aliso Viejo, CA Medical Doctor
NPI 1811195563 CMS profile 870171
9 Goldenrain, Aliso Viejo, CA 92656
General payments
$191
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Peter Phan of Aliso Viejo, CA is reported in the CMS Open Payments database as having received $191 across 4 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 49th percentile of Nuclear Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
2 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $48 | 2 | |
| 2019 | General | $144 | 2 |
Beside peers
- Peter Phan
- Nuclear Medicine median
- Middle half of Nuclear Medicine
- National median
In program year 2025, general payments to Peter Phan were reported at $48. Among 197 Nuclear Medicine profiles paid that year, the median was $146 and the middle half received between $40 and $372.
Show as a table
| Year | Peter Phan | Nuclear Medicine median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $144 | $125 | $54–$531 | $163 |
| 2020 | $0 | $99 | $34–$2,125 | $114 |
| 2021 | $0 | $96 | $22–$874 | $132 |
| 2022 | $0 | $102 | $38–$240 | $149 |
| 2023 | $0 | $123 | $51–$257 | $160 |
| 2024 | $0 | $121 | $51–$390 | $164 |
| 2025 | $48 | $146 | $40–$372 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Billing to Medicare
Part B · data year 2024 · 129 billing codesPaid by Medicare
$68,675
Medicare patients
1,399
Services billed
2,548
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Diabetes | 48% | |
| Arthritis | 35% | |
| Heart failure | 32% | |
| Ischemic heart disease | 32% | |
| Chronic kidney disease | 32% | |
| Atrial fibrillation | 25% | |
| Depression | 25% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
4 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Nuclear Medicine in California
Hossein Jadvar
Nuclear Medicine · Los Angeles, CA
Michael Dae
Nuclear Medicine · San Francisco, CA
Ernest Belezzuoli
Nuclear Medicine · San Diego, CA
Johannes Czernin
Nuclear Medicine · Los Angeles, CA
Gholam Berenji
Nuclear Medicine · Los Angeles, CA
Shahram Bonyadlou
Nuclear Medicine · Los Angeles, CA
Related records
Nuclear Medicine in California
Practitioners in the same specialty and state, ranked by reported value.
All Nuclear Medicine
Everyone recorded under this specialty, nationwide.
Doctors in California
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.